A conjugated or labeled antibody is a polyclonal or monoclonal antibody with an attached reporter molecule that generates a signal through color, fluorescence, radioactivity, or enzymatic activity, ...

Antibody-drug conjugates (ADCs) are transforming targeted cancer therapy, with innovations in conjugation chemistry and payload-linker technologies driving improvements in efficacy, stability, and ...

Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the ...

Ajinomoto Co., Inc. has signed a licensing agreement with Astellas Pharma Inc. for the use of AJICAP—an antibody-drug conjugate (ADC) development and manufacturing technology—as part of its CDMO ...

An antibody-drug conjugate (ADC) is a newly developed, highly-targeted type of cancer therapeutic. ADCs are created by grafting monoclonal antibodies to a cytotoxic payload. This new type of cancer ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the ...

EMA grants Orphan Drug Designation to GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227 to treat pulmonary neuroendocrine carcinoma: London, UK Wednesday, October 29, 2025 ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to the antibody-drug conjugate JSKN003 for the ...

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with ...